NO20076371L - Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner - Google Patents

Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner

Info

Publication number
NO20076371L
NO20076371L NO20076371A NO20076371A NO20076371L NO 20076371 L NO20076371 L NO 20076371L NO 20076371 A NO20076371 A NO 20076371A NO 20076371 A NO20076371 A NO 20076371A NO 20076371 L NO20076371 L NO 20076371L
Authority
NO
Norway
Prior art keywords
biphenylylazetidin
phenolic
preparation
ones
derivatives
Prior art date
Application number
NO20076371A
Other languages
English (en)
Norwegian (no)
Inventor
John J Talley
Timothy C Barden
Wayne C Schairer
Peter Lee
Eduardo J Martinez
Original Assignee
Microbia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbia Inc filed Critical Microbia Inc
Publication of NO20076371L publication Critical patent/NO20076371L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • C07F7/1872Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20076371A 2005-05-11 2007-12-10 Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner NO20076371L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67978505P 2005-05-11 2005-05-11
PCT/US2006/018153 WO2006122216A2 (en) 2005-05-11 2006-05-11 Processes for production of phenolic 4-biphenylylazetidin-2-ones

Publications (1)

Publication Number Publication Date
NO20076371L true NO20076371L (no) 2008-02-11

Family

ID=37397290

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076371A NO20076371L (no) 2005-05-11 2007-12-10 Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner

Country Status (15)

Country Link
US (1) US20080200669A1 (enExample)
EP (1) EP1885703A4 (enExample)
JP (1) JP2008540557A (enExample)
KR (1) KR20080017345A (enExample)
CN (1) CN101218213A (enExample)
AU (1) AU2006244043A1 (enExample)
BR (1) BRPI0608970A2 (enExample)
CA (1) CA2608075A1 (enExample)
EA (1) EA200702464A1 (enExample)
IL (1) IL187287A0 (enExample)
MA (1) MA29539B1 (enExample)
MX (1) MX2007014172A (enExample)
NO (1) NO20076371L (enExample)
WO (1) WO2006122216A2 (enExample)
ZA (1) ZA200710721B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
BRPI0611531A2 (pt) * 2005-05-09 2010-09-21 Microbia Inc agentes de acoplamento de benzenofosfonato de organometal e método de geração de ligação carbono-carbono
US20090099355A1 (en) * 2005-05-25 2009-04-16 Microbia, Inc. Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2414339B1 (en) * 2009-04-02 2013-01-16 Lupin Ltd. Kinetic resolution of (4s)-4-phenyl-3-[5(rs)-(4-fluorophenyl)-5-hydroxypentanoyl]-1,3 oxazolidin 2-one to (5s) isomer via lipase catalyzed enantioselective esterification of the (5r) isomer
AU2010288523A1 (en) 2009-08-26 2012-03-15 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102285932B (zh) * 2011-09-01 2013-06-12 浙江大学 一种依替米贝中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW223059B (enExample) * 1991-07-23 1994-05-01 Schering Corp
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
CA2353981C (en) * 1998-12-07 2005-04-26 Schering Corporation Process for the synthesis of azetidinones
MXPA03005155A (es) * 2000-12-21 2003-09-10 Aventis Pharma Gmbh 1,2-difenilazetidinonas novedosas, procesos para su preparacion, farmacos que contienen compuestos y su uso para el tratamiento del metabolismo afectado de los lipidos.
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
AU2002258605B2 (en) * 2001-03-28 2006-01-12 Merck Sharp & Dohme Corp. Enantioselective synthesis of azetidinone intermediate compounds
CN1805926A (zh) * 2003-05-05 2006-07-19 兰贝克赛实验室有限公司 二苯基氮杂环丁酮衍生物的反式异构体的制备方法
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
EP1877067A1 (en) * 2005-04-26 2008-01-16 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
WO2006121861A2 (en) * 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones

Also Published As

Publication number Publication date
JP2008540557A (ja) 2008-11-20
CN101218213A (zh) 2008-07-09
EP1885703A4 (en) 2009-09-02
EP1885703A2 (en) 2008-02-13
WO2006122216A2 (en) 2006-11-16
MX2007014172A (es) 2008-04-02
WO2006122216A3 (en) 2007-09-13
ZA200710721B (en) 2008-10-29
KR20080017345A (ko) 2008-02-26
IL187287A0 (en) 2008-08-07
CA2608075A1 (en) 2006-11-16
US20080200669A1 (en) 2008-08-21
BRPI0608970A2 (pt) 2010-02-17
AU2006244043A1 (en) 2006-11-16
EA200702464A1 (ru) 2008-04-28
MA29539B1 (fr) 2008-06-02

Similar Documents

Publication Publication Date Title
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
WO2007085895A3 (en) Fap inhibitors
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
NO20074093L (no) Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
MY150596A (en) Hsp90 inhibitors
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
TW200716525A (en) Process for preparation of sulfamide derivatives
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
WO2009040314A3 (de) Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
DE502007003531D1 (de) Verfahren zum herstellen von alkylaniliden aus halogenbenzolderivaten
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200728310A (en) Process for the preparation of ferri-succinylcasein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application